Atrial Dysfunction Assessed by Cardiac Magnetic Resonance as an Early Marker of Fabry Cardiomyopathy.

Andrea Bernardini,Antonia Camporeale,Maurizio Pieroni,Federico Pieruzzi,Stefano Figliozzi,Paola Lusardi,Marco Spada,Renzo Mignani,Alessandro P. Burlina,Francesca Carubbi,Yuri Battaglia,Francesca Graziani,Silvia Pica,Lara Tondi,Kelvin Chow,S Boveri,Iacopo Olivotto,Massimo Lombardi

Atrial Dysfunction Assessed by Cardiac Magnetic Resonance as an Early Marker of Fabry Cardiomyopathy.

2020

Andrea Bernardini
Antonia Camporeale
Maurizio Pieroni
Federico Pieruzzi
Stefano Figliozzi
Paola Lusardi
Marco Spada
Renzo Mignani
Alessandro P. Burlina
Francesca Carubbi
Yuri Battaglia
Francesca Graziani
Silvia Pica
Lara Tondi
Kelvin Chow
S Boveri
Iacopo Olivotto
Massimo Lombardi

Anderson-Fabry disease (AFD) cardiomyopathy is characterized by glycosphingolipid (Gb3) storage in all cellular components, with consequent left ventricular hypertrophy (LVH). Gb3 accumulation also involves atrial myocytes ([1][1]), ultimately leading to left atrial (LA) enlargement and reduced

Keywords:

atrial myocytes
Cardiomyopathy
Cardiology
left atrial
Medicine
Internal medicine
Glycosphingolipid
Muscle hypertrophy
cardiac magnetic resonance

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations